Data show Anaphylm maintains consistent stability and potency under extreme temperature and real-world conditions, including heat, freezing, and ...

Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that the abstract for its ...

Corbus Pharmaceuticals (CRBP) announced that the abstract for its first-in-human dose escalation clinical study conducted in the United States ...

SAN FRANCISCO -- Janus kinase (JAK) inhibitors appeared to be a safe, effective option for treating inflammatory bowel ...

Data presented at the 2025 Crohn's and Colitis Congress PALI-2108 demonstrated to effectively reduce colitis symptoms in DSS mouse model without CNS toxicity associated with systemic exposure Company ...

NORWOOD, Mass. - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a $119 million market cap biopharmaceutical company, announced the release of an abstract detailing its Phase 1 clinical study of ...

Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Year-end Report January-December 2024. The full report is available on the Company's website. “Stronger liquidity will ensure our ...

South Korea showcases top 10 innovative medical devices at annual report meeting South Korea reveals its top ten groundbreaking healthcare technologies at a major annual event ...

A hate preacher who claimed it was better to be a paedophile than miss prayers has been invited to speak in Britain, despite ...